|
|
Sangamo Therapeutics, Inc.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Re: SGMO timeline Below is the timeline since i last posted 8 months ago.. Have to start digging again to make updates since i havent been paying attention. Maybe biotech winter is finally over and time to pay attention again. It seems like there have been lots of changes and delays in timeline ( no surprise ) What is happening to GILD CART and CNS programs?- seems i have to start digging though the posts :) I see they have been busy printing shares and raising cash to stay alive :) SGMO timelineSGMO event timeline update - replying to my timeline if you want to see changes. Although all events are important for the company, I will highlight the ones I feel will have the most effect on share price ( not coincidentally its human trial data ) Where SGMO is now in trials: Hemo A- Phase 3 started dosing 3q 2020- clinical hold 4q 2021- > 50% dosed Fabrys- phase 1 dosing started 3q 2020- dosed 3 cohorts- 5 patients total Sickle cell- phase 1/2- 4 patients dosed TxCell T reg for renal transplant- enrolled 1/ dose 1h 2022? 1H 2022 Fabry- data in phase 1 trial 2H 2022 GILD- CART IND IND CNS Tau with Biogen CART-Reg data in renal transplant patients Sanofi- sickle data- Hemo A Pfizer updated phase 3 data Fabry- renal biopsy data cohort 3 2023 Hemo A Pfizer full phase 3 data Fabry 1 year extended cohort 3 data Hemo A FDA accelerated filing - Pfizer CART-Reg IND ( MS vs IBD) Dose CNS Tau with Biogen CNS Parkinson's IND with Biogen CNS Autism IND with Novartis GILD 2nd CART IND Sanofi- sickle data 2024 Launch Hemo A commercially * Fabry file for FDA approval and launch |
||||||||||||
|
|
return to message board, top of board |
| Msg # | Subject | Author | Recs | Date Posted |
| 166841 | Re: SGMO timeline | 2fingers | 23 | 8/6/2022 10:37:05 AM |
